Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Duarte, Rafael F.; Canals, Carmen; Onida, Francesco; Gabriel, Ian; Arranz, Reyes; Arcese, William; Ferrant, Augustin; Kobbe, Guido; Narni, Franco; Deliliers, Giorgio Lambertenghi; Olavarría, Eduardo; Schmitz, Norbert; Sureda, Anna

doi:10.1200/jco.2010.29.3241

Cited by 181 publications

(168 citation statements)

References 23 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…In contrast, the durable remissions observed following allogeneic transplantation may be explained by the graft versus lymphoma immune response [365,366]. A retrospective analysis of 60 patients with advanced-stage MF/SS who underwent allogeneic stem cell transplantation was recently reported [367]. In this series, patients had received a median of four prior therapies before undergoing either reduced-conditioning (73%) or myeloablative (27%) conditioning before related (75%), or matched-unrelated donor (25%) transplantation.…”

Section: High-dose Chemotherapy and Hematopoietic Stem Cell Transplanmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Section: High-dose Chemotherapy and Hematopoietic Stem Cell Transplanmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

show abstract

“…2 Allogenic SCT (allo-SCT) is increasingly used as an alternative strategy, based on a potent graft-versus-lymphoma effect (GvL). However, data from retrospective [3][4][5][6][7][8][9][10][11] and prospective non-randomized studies 12 are insufficient to recommend allo-SCT as first-line treatment. The European Bone Marrow Transplantation Society currently considers allo-SCT to be an option for selected patients with chemosensitive disease in first or second complete response (CR), if a sibling or unrelated HLA-matched donor is available (grade 2 recommendations).…”

Section: Introductionmentioning

confidence: 99%

“…5 Finally, a negative impact on survival, due to a high relapse rate (70%), has been reported with T-cell-depleted grafts in primitive cutaneous T-cell lymphoma (TCL). 7 Few data are available on treatment options after PTCL relapse. In an Italian series, 76% of 25 patients who relapsed after transplantation died, within a median of 8 months.…”

Section: Introductionmentioning

confidence: 99%

“…5 Some responses have been reported after immunomodulation based on tapering of immunosuppressive drugs and/or on donor lymphocyte infusion (DLI). [4][5][6][7][8]13,14 To better assess the possible GvL effect in PTCL, we studied 63 patients who relapsed after allo-SCT, focusing on the impact of immunomodulation based on tapering of immunosuppressive drugs and/or DLI on subsequent outcome.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Mamez

Lévy

Chevallier

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheral T-cell lymphoma who relapsed after allogeneic transplant in 27 SFGM-TC centers. Relapse occurred after a median of 2.8 months. Patients were then treated with nonimmunologic strategies (chemotherapy, radiotherapy) and/or immune modulation (donor lymphocyte infusions (DLI) and/or discontinuation of immunosuppressive therapy). Median overall survival (OS) after relapse was 6.1 months (DLI group: 23.6 months, non-DLI group: 3.6 months). Among the 14 patients who received DLI, 9 responded and 2 had stable disease. Among the remaining 49 patients, a complete response accompanied by extensive chronic GvHD was achieved in two patients after tapering of immunosuppressive drugs. Thirty patients received radio-chemotherapy, with an overall response rate of 50%. In multivariate analysis, chronic GvHD (odds ratio: 11.25 (2.68-48.21), P = 0.0009) and skin relapse (odds ratio: 4.15 (1.04-16.50), P = 0.043) were associated with a better response to treatment at relapse. In a time-dependent analysis, the only factor predictive of OS was the time from transplantation to relapse (hazards ratio: 0.33 (0.17-0.640), P = 0.0009). This large series provides encouraging evidence of a true GvL effect in this disease.

show abstract

“…Similar results were obtained after reduced-intensity conditioning allo-SCT in 17 patients who were allografted for relapsed or refractory PTCL. 3 Another argument in favor of a GVL effect is the poor efficacy of T-depleted transplantation: Duarte et al 4 reported 2-year PFS rates of 17% after ex vivo T-cell-depleted allo-HSCT and 39% after T-cellrepleted allo-HSCT.…”

mentioning

confidence: 99%

Graft-versus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation

Mamez

Souchet

Roos‐Weil

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Abstract: Allogeneic transplantation is a valid therapeutic alternative for high-risk patients with advanced-stage MF/SS. Our data also suggest the existence of a clinically relevant graft-versus-lymphoma effect in MF/SS.

Cited by 181 publications

References 23 publications

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Graft-versus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation

Contact Info

Product

Resources

About